Abeona therapeutics announces new preclinical data from its aav ophthalmology program at the 26th annual meeting of the american society of gene & cell therapy (asgct)

Animal proof-of-concept for aav-based gene therapies for stargardt disease, x-linked retinoschisis and autosomal dominant optic atrophy animal proof-of-concept for aav-based gene therapies for stargardt disease, x-linked retinoschisis and autosomal dominant optic atrophy
ABEO Ratings Summary
ABEO Quant Ranking